<DOC>
	<DOCNO>NCT01650727</DOCNO>
	<brief_summary>The purpose study determine maximum-tolerated dose ( MTD ) dinaciclib therapy combination rituximab chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) .</brief_summary>
	<brief_title>A Study Dinaciclib Combination With Rituximab Participants With Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma ( P07974 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Must receive least one prior therapy include either fludarabine equivalent nucleoside analogue alternative regimen Diagnosis chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) Eastern Cooperative Oncology Group ( ECOG ) Performance status ≤ 2 Women childbearing potential sexually active , , include female subject female sexual partner male subject , must agree use medically accept method contraception prior enrollment , receive protocolspecified treatment , 12 month stop study treatment . Women childbearing potential currently sexually active must agree use medically accept method contraception become sexually active participate study . Life expectancy ≥12 week Symptomatic brain metastasis primary central nervous system malignancy Treatment chemotherapy biologic therapy within 4 week prior enrollment Nonhematological toxicity prior therapy Presence serious uncontrolled infection define infection require hospital admission and/or parenteral antibiotic Known human immunodeficiency virus ( HIV ) infection know HIVrelated malignancy Clinically active hepatitis B C define disease require therapy Women breastfeeding , pregnant , intend become pregnant Prior allogeneic bone marrow transplant ( auto hematopoietic stem cell transplantation [ HSCT ] allow fully recover ) Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer cancer subject consider physician 2 year survival expectation Any investigational drug within 4 week prior start treatment Concurrently receive treatment clinical study Previously treat cyclin dependent kinase ( CDK ) inhibitor ( e.g. , dinaciclib flavopiridol ) Active autoimmune anemia idiopathic thrombocytopenic purpura ( ITP ) unless stable , defined responsive corticosteroid standard therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>